Compounds > poloxalene
Page last updated: 2024-08-22

poloxalene and Disease Models, Animal

poloxalene has been researched along with Disease Models, Animal in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (55.56)18.2507
2000's0 (0.00)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Banks, WA; Farr, SA; Kabanov, AV; Poon, CD; Yi, X; Yuan, D1
Chen, B; Chen, S; Chen, Z; Fang, Z; Li, Z; Ni, G; Ning, Y; Qin, J; Wu, C; Zhou, J; Zhou, L1
Baska, P; Bertagnolli da Rosa, L; Dezen, D; Duarte, MMMF; Henker, LC; Januszkiewicz, K; Lucca, NJ; Mendes, RE; Moresco, RN; Norbury, L; Piva, MM; Prior, KC; Schwertz, CI1
Boyle, SM; Contreras-Rodriguez, A; Jain-Gupta, N; Sriranganathan, N; Vemulapalli, R; Witonsky, SG1
Dhindsa, HS; Edwards, BA; Howell, JM; Stair, TO1
Anderson, PG; Bilodou, L; Hearn, JA; Iyer, S; Liu, MW; Luo, JF; Roubin, GS1
Emeson, EE; Johnston, TP; Palmer, WK1
Dejoy, SQ; Desai, NR; Gibbons, JJ; Kerwar, SS; Oronsky, AL; Pickett, WC; Torley, LW1
Henry, RL; Leach, RE1

Other Studies

9 other study(ies) available for poloxalene and Disease Models, Animal

ArticleYear
Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity.
    Journal of controlled release : official journal of the Controlled Release Society, 2014, Oct-10, Volume: 191

    Topics: Animals; Anti-Obesity Agents; Blood-Brain Barrier; Body Weight; Cells, Cultured; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Carriers; Drug Stability; Eating; Feeding Behavior; Injections, Intravenous; Injections, Subcutaneous; Leptin; Male; Mice; Obesity; Permeability; Poloxalene; Technology, Pharmaceutical

2014
Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy.
    Biomaterials, 2016, Volume: 97

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chronic Disease; Disease Models, Animal; Drug Resistance; Enbucrilate; Epilepsy, Temporal Lobe; Female; Hippocampus; Lithium; Nanoparticles; Phenytoin; Pilocarpine; Poloxalene; Rats, Sprague-Dawley; Reproducibility of Results; Seizures; Tissue Distribution

2016
Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats.
    Vaccine, 2017, 01-23, Volume: 35, Issue:4

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Helminth; Antigens, Helminth; Cytokines; Disease Models, Animal; Fascioliasis; Feces; Immunoglobulin G; Male; Myosin Light Chains; Parasite Egg Count; Parasite Load; Poloxalene; Rats, Wistar; Recombinant Proteins; Th1 Cells; Th2 Cells; Vaccines, Synthetic

2017
Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.
    FEMS immunology and medical microbiology, 2012, Volume: 66, Issue:3

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Brucella melitensis; Brucella Vaccine; Brucellosis; Disease Models, Animal; Exosomes; Female; Immunoglobulin G; Macrophages; Mice; Mice, Inbred BALB C; Poloxalene; Tumor Necrosis Factor-alpha; Vaccines, Subunit

2012
Effect of scrubbing and irrigation on staphylococcal and streptococcal counts in contaminated lacerations.
    Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:12

    Topics: Animals; Colony Count, Microbial; Disease Models, Animal; Disinfection; Guinea Pigs; Poloxalene; Povidone-Iodine; Staphylococcal Skin Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Therapeutic Irrigation; Wound Infection

1993
Reduction of thrombus formation without inhibiting coagulation factors does not inhibit intimal hyperplasia after balloon injury in pig coronary arteries.
    Coronary artery disease, 1996, Volume: 7, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Animals; Blood Coagulation Factors; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Fibrinolytic Agents; Hyperplasia; Infusions, Intravenous; Poloxalene; Random Allocation; Swine; Thrombolytic Therapy; Tunica Intima

1996
The poloxamer 407-induced hyperlipidemic atherogenic animal model.
    Medicine and science in sports and exercise, 1997, Volume: 29, Issue:11

    Topics: Animals; Arteriosclerosis; Cholesterol; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Injections, Intravenous; Mice; Mice, Inbred C57BL; Poloxalene; Rats

1997
Pluronic F 127 liquid sensitizes mice to low doses of Escherichia coli lipopolysaccharide.
    Critical care medicine, 1992, Volume: 20, Issue:10

    Topics: Animals; Body Temperature; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli; Evaluation Studies as Topic; Immunization; Injections, Intraperitoneal; Interleukin-6; Lethal Dose 50; Lipopolysaccharides; Liver Function Tests; Mice; Mice, Inbred BALB C; Poloxalene; Shock, Septic; Sodium Chloride; Temperature; Triglycerides; Tumor Necrosis Factor-alpha

1992
Reduction of postoperative adhesions in the rat uterine horn model with poloxamer 407.
    American journal of obstetrics and gynecology, 1990, Volume: 162, Issue:5

    Topics: Animals; Body Temperature; Disease Models, Animal; Female; Gels; Peritoneal Diseases; Peritoneum; Poloxalene; Polyethylene Glycols; Postoperative Complications; Rats; Rats, Inbred Strains; Tissue Adhesions; Uterine Diseases; Uterus

1990